Mahamaya Lifesciences Ltd (MAHALIFE)

About

Mahamaya Lifesciences operates in pesticides and agrochemicals, a foundational segment within India's Materials sector. At ₹443.31 Cr market cap, it is a small-cap with 56.35% promoter ownership. High stock volatility (52-week range ₹113.85–₹201.25) and limited financial disclosure characterize its risk profile.

Face value: ₹10

Market cap

₹412 Cr

P/E

24.6×

P/B

—

Dividend yield

0%

ROE

—

ROCE

—

Debt / equity

—

OPM

10.1%

EPS (TTM)

₹7.1

Book value

—

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Multiple key metrics are unavailable (PE, ROE, OPM, D/E) — profitability and capital efficiency cannot be assessed; verify audited financial statements
Foreign institutional holding declined from 6.39% (Sept 2025) to 4.77% (March 2026), suggesting reduced external investor confidence
Small market cap (₹443 Cr) and high stock volatility (52-week range ₹113.85–₹201.25) constrain institutional participation and trading liquidity
Agrochemical sector is cyclical with exposure to input costs and crop cycles; verify company's cost management and margin resilience

Generated analysis · source review pending

Growth drivers

Stock price recovery from 52-week low ₹113.85 to current ₹189.45 reflects renewed interest; verify if supported by earnings improvement or temporary sentiment
Public shareholding increased from 32.59% to 36.36% over six months, signalling growing retail participation; assess whether this reflects operational progress
Market cap ₹443 Cr allows room to consolidate smaller players or gain share if company has competitive advantages; verify market position and strategic plans
Founder ownership stable at 56.35% enables long-term capital deployment; verify planned investments in specialty agrochemicals or new geographies

Generated analysis · source review pending

209 historical price candles were omitted because the exchange source has not been verified.

₹176.1-2.7%1Y

Research score

Structured signal from quality, growth, valuation and momentum.

35/100

Business quality: 19
Valuation: 51

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Upl LimitedUPLUPL	₹43,628 Cr	₹65,674 Cr	₹52,804 Cr	₹9,326 Cr	17.9%	₹2,020 Cr	4.3%	11.2%	6%	135
Sumitomo Chemical India LimitedSUMICHEMSUMICHEM	₹20,842 Cr	₹20,844 Cr	₹3,245 Cr	₹685 Cr	20.7%	₹579 Cr	16.8%	23.1%	17.3%	155
Bayer Cropscience LimitedBAYERCROPBAYERCROP	₹15,958 Cr	—	₹5,472 Cr	₹688 Cr	15.4%	₹568 Cr	12.1%	28.4%	23.7%	300
Sharda Cropchem LimitedSHARDACROPSHARDACROP	₹6,397 Cr	₹6,397 Cr	₹5,357 Cr	₹1,047 Cr	20.4%	₹626 Cr	12.9%	28%	24.2%	125
Dhanuka Agritech LimitedDHANUKADHANUKA	₹4,217 Cr	₹4,259 Cr	₹2,035 Cr	₹417 Cr	20.5%	₹297 Cr	14.6%	28.9%	22.3%	160
Rallis India LimitedRALLISRALLIS	₹3,884 Cr	₹3,942 Cr	₹2,604 Cr	₹274 Cr	10.5%	₹164 Cr	6.3%	13.2%	10%	104
Bhagiradha Chemicals & Industries LimitedBHAGCHEMBHAGCHEM	₹3,063 Cr	₹3,294 Cr	₹607 Cr	₹79 Cr	10.7%	₹28 Cr	3.4%	4.8%	2.6%	148
Nacl Industries LimitedNACLINDNACLIND	₹3,054 Cr	₹3,355 Cr	₹1,519 Cr	₹106 Cr	6.5%	₹12 Cr	0.3%	11.8%	0.8%	105
Gsp Crop Science LimitedGSPCROPGSPCROP	₹2,113 Cr	₹2,373 Cr	₹1,517 Cr	₹185 Cr	12.2%	₹-3 Cr	6.2%	20.7%	-0.4%	121
Bharat Rasayan LimitedBHARATRASBHARATRAS	₹1,658 Cr	₹1,659 Cr	₹1,203 Cr	₹177 Cr	16%	₹140 Cr	11.7%	17.5%	12.1%	219
Insecticides (India) LimitedINSECTICIDINSECTICID	₹1,655 Cr	₹1,799 Cr	₹2,060 Cr	₹210 Cr	10.6%	₹125 Cr	6.5%	17.1%	12.1%	168
Astec Lifesciences LimitedASTECASTEC	₹1,580 Cr	₹2,029 Cr	₹441 Cr	₹6 Cr	-1%	₹-67 Cr	-18.1%	-9.3%	-25.9%	263

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Standalone figures · ₹ crore

₹ Cr	Mar 2026
Revenue	329
COGS	275
Gross profit	54
	21
Operating profit (EBITDA)	33
OPM %	10.1%
Depreciation	2
Interest	8
	1
Profit before tax	24
Tax	7
Tax %	30.5%
PAT	17
PAT margin %	5.1%
EPS (₹)	8.4

₹ Cr	Mar 2026
Equity capital	—
Reserves	—
Borrowings	—
	311
Total equity & liabilities	311
Fixed assets	23
CWIP	—
Investments	0
	288
Total assets	311

₹ Cr	Mar 2026
	-30
	-16
	81
Net cash flow	35
Free cash flow	-38
CFO / Operating profit %	-88.9%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

No ratio history

Ratios derive from annual statements, which haven't been ingested yet.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2025	Mar 2026
	56.35%	56.35%
	6.39%	4.77%
	4.67%	2.52%
Government	0%	0%
	32.59%	36.36%
No. of shareholders	1,034	584

Promoter holding up 0 percentage points since Sep 2025.

9 deals · 19 Aug 2026 – 22 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
22 Sept 2026	BHATIA SURESH	Bulk	BSE	Buy	3,30,000	₹181.66	₹5.99 Cr
22 Sept 2026	SANJAY POPATLAL JAIN	Bulk	BSE	Buy	3,22,800	₹181.97	₹5.87 Cr
22 Sept 2026	NU HEIGHTS AGENCY PRIVATE LIMITED	Bulk	BSE	Sell	1,71,600	₹182.76	₹3.14 Cr
22 Sept 2026	ABUNDANTIA CAPITAL VCC - ABUNDANTIA CAPITAL III	Bulk	BSE	Sell	1,32,000	₹182.50	₹2.41 Cr
22 Sept 2026	NU HEIGHTS AGENCY PRIVATE LIMITED	Bulk	BSE	Buy	19,200	₹180.14	₹0.35 Cr
21 Sept 2026	SANJAY POPATLAL JAIN	Bulk	BSE	Buy	1,56,000	₹180.00	₹2.81 Cr
19 Aug 2026	NIKHIL K S	Bulk	BSE	Buy	2,62,800	₹190.30	₹5.00 Cr
19 Aug 2026	KIFS ENTERPRISE	Bulk	BSE	Buy	2,50,800	₹190.24	₹4.77 Cr
19 Aug 2026	QAPLA INVESTMENTS	Bulk	BSE	Sell	1,18,800	₹190.00	₹2.26 Cr

1–9 of 9

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Krishnamurthy GanesanManaging Director
Prashant Krishna MurthyExecutive Director
Lalitha KrishnamurthyWhole Time Director
Charudatta Digambar MayeeIndependent Director
Gopal Krishna RajuIndependent Director
Sekhar Kavasseri RajagopalanIndependent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Mahamaya Lifesciences Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

11

Offer and rights documents

1

Mahamaya Lifesciences Limited — DRHPListing · 27 Feb 2025

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

11 announcementsExport CSV

25 Aug 2026, 1:43 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Directorate

Change in Directorate PDF

25 Aug 2026, 1:38 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

25 Aug 2026, 1:30 pmCompany Update

Appointment of Company Secretary and Compliance Officer

Appointment of Company Secretary / Compliance Officer PDF

Date	Category	Subject	Filing
25 Aug 2026, 1:43 pm	Company Update Change in Directorate	Announcement under Regulation 30 (LODR)-Change in Directorate	PDF
25 Aug 2026, 1:38 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management

Loading announcements…

Mahamaya Lifesciences Ltd

About

Key insights

Key risks

Growth drivers

Research score

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

No ratio history

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Offer and rights documents

Events

No events on record

Announcements

No ratio history

No events on record

Quarterly record

Bulk & block deals

Board and management

Announcements

Offer and rights documents

Not in the F&O segment

No fund holdings on record

Profit & loss

Balance sheet

Cash flow